Sudeep Pharma
Sudeep Pharma
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has delivered good profit growth of 39.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
Weaknesses
1- Stock is trading at 15.4 times its book value
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 9d agoSudeep Pharma Ltd is a small-cap healthcare company with a market cap of ₹15,079 Cr, trading at a PE of 79.7x. The company has delivered strong profit growth of 39% CAGR over five years and maintains a healthy ROE of 25–32%, but the stock trades at 16.6x book value, reflecting a steep premium to fundamentals.
- Compounded profit growth of 39% CAGR over 5 years indicates strong earnings momentum
- 3-year ROE of 32% and 5-year ROE of 32% reflect consistent and high capital efficiency
- TTM sales growth of 24% suggests continued top-line traction in the current period
- 5-year compounded sales CAGR of 24% demonstrates sustained revenue expansion over a longer horizon
- TTM profit growth of 20% shows the company continues to grow earnings in the most recent period
- 3-year compounded profit CAGR of 40% outpaces the 3-year sales CAGR of 14%, indicating margin expansion
- Last-year ROE of 25%, while slightly lower than the 3-year average of 32%, still remains well above industry norms for small-cap pharma
- PE ratio of 79.7x is significantly elevated, pricing in aggressive future growth and leaving limited margin of safety
- Price-to-book ratio of 16.6x is extremely high, indicating the stock trades at a steep premium to its net asset value
- Dividend yield of just 0.12% offers negligible income return to shareholders
- ROE has declined from 32% (3-year average) to 25% in the last year, a drop of 7 percentage points suggesting potential return compression
- TTM profit growth of 20% has decelerated sharply from the 3-year CAGR of 40%, raising questions about earnings sustainability
- Debt-to-equity ratio is undisclosed (null), limiting visibility into the company's leverage and financial risk profile
- Key data points such as 52-week high/low and EPS are unavailable, making comprehensive valuation assessment difficult
- Small-cap pharma companies with market cap of ₹15,079 Cr can face higher volatility and liquidity risks compared to large-cap peers
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 28d ago- Q1FY26 profit jumps 30% YoY Aug 5
Consolidated net profit rose 29.8% YoY to ₹405.87 lakh in Q1FY26, driven by a 26% surge in revenue from the pharmaceutical and nutrition segment.
- AGM approves battery expansion Aug 4
37th AGM on Aug 4, 2026 adopted FY26 financials with ₹642.3 crore revenue and approved entry into advanced battery materials along with new board appointments.
- Q1FY27 earnings call scheduled Jul 27
Sudeep Pharma will host an earnings call on August 5, 2026 at 11:00 AM IST led by MD Sujit Bhayani to discuss Q1FY27 results.
TL;DR: Sudeep Pharma is delivering strong profit growth with Q1FY26 net profit up 30% YoY on robust revenue gains. The company is diversifying into advanced battery materials, signaling ambitions beyond its pharma core. No visible headwinds in recent news, though execution risk on the new battery segment remains a watch item. The near-term trend is positive with momentum in both earnings and strategic expansion.
Quarterly Results
| Particulars | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| PBT | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS in Rs | 128 | 2.95 | 4.54 | 3.17 | 4.71 | 4.2 | 4.33 | 3.59 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Expenses | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 443 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 34% |
| Other Income | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 29 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| PBT | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | — |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS in Rs | 128 | 237 | 356 | 442 | 945 | 14.27 | 15.31 | 16.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 |
| Other Liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Fixed Assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Investing | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Financing | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | 0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/OP | 62 | 104 | 22 | 78 | 60 | 47 | 56 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | — | 36% | 36% | 33% | 49% | 36% | 28% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sudeep Pharma insights
64 extracted metrics + investor summaries across FY20–FY27.
Documents
Frequently Asked Questions about Sudeep Pharma
What does Sudeep Pharma Ltd do?
Where is Sudeep Pharma Ltd (SUDEEPPHRM) listed?
Which sector does Sudeep Pharma Ltd belong to?
What is the market capitalisation of Sudeep Pharma Ltd?
What is the PE ratio of Sudeep Pharma Ltd?
What is the 52-week high and low of Sudeep Pharma Ltd?
Does Sudeep Pharma Ltd pay dividends?
What is the Return on Equity (ROE) of Sudeep Pharma Ltd?
Company Information
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUDEEPPHRM.md for Sudeep Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.